Effect of Medicago Sativa on Oral Glucose Tolerance in Healthy Adults

• Status: Completed
• Trial end date: 2018-01-30
• Target enrollment: 0
• Participant gender: All

Summary

Previous preclinical investigations have found that Medicago sativa promotes the decrease of glucose concentrations. To evaluate the acute effect of Medicago sativa administration on glucose tolerance, insulin secretion, and insulin sensitivity in healthy individuals.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Guadalajara
• Treatments: Insulin; Insulin, Globin Zinc

Criteria

Inclusion Criteria:

• Fasting plasma glucose ≤99 mg/dL.

• Two hours postload plasma glucose (100 a 139 mg/dL).

• Body mass Index: 25 -39.9 kg/m2.

• body weight stable over the last 3 months.

• Women in follicular phase of the menstrual cycle (days 3 to 8 of the cycle) at the time of laboratory tests.

• Sedentary.

• Nonsmokers.

• Body weight unchanged upper to 5% for at least 3 moths before the study.

Exclusion Criteria:

• Women in pregnancy and/or breastfeeding

• Physical or mental disability that makes it impossible to perform the intervention.

• Diagnosis of hypertension or heart failure.

• Untreated thyroid disease.

• Consumption of oral agents or other medications or supplements with proven properties that modify the behavior of glucose and lipids (oral hypoglycemic agents, insulin, lipid-lowering).

• Diagnosis of liver disease or elevation twice of the upper normal value of liver enzymes.

• Diagnosis of renal disease or creatinine >1.5 mg/dL.

• Diagnosis of prediabetes: Fasting plasma glucose ≥100 mg/dL and/or 2h-OGTT ≥140mg/dL and/or glycated hemoglobin A1c (A1C) between 5.7 - 6-4 %.

• Diagnosis of Type 2 Diabetes Mellitus (T2DM): Fasting glucose ≥ 126 mg / dL and/or 2h-OGTT ≥ 200 mg/dL .

• Total Cholesterol ≥ 280 mg/dL.

• Triglycerides ≥ 300 mg/dL.

• Known allergy to calcined magnesia or Medicago sativa.